This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The company developed methods to identify disease-driving condensates, model them, and create systems for effective drug discovery targeting these condensates. The aim is to establish condensate biology as a fundamental branch of cellbiology – “cellbiology 2.0”
This major shift to the orthodox tradition of using animal experiments in drug testing dates back the Aristotle’s time and cemented 80 years ago with initial federal mandate of drug safety regulation of 1938.
When I was studying cellbiology, looking at how cells divide, I couldn’t fathom how math could possibly fit into that. My undergraduate studies focused on biochemistry and cellbiology, so very much STEM-based, but my professors and mentors noticed my penchant for critical thinking which led me to consider law.
That includes those involved in regulating our appetites and our moods, via a class of G proteins known as inhibitory G proteins (G i ). They share a common architecture and bind a relatively limited number of intracellular signaling proteins called G proteins.
The general notion is that patients should be viewed individually, rather than strictly as members of some larger general population, and that their specific genetic background, environment, and lifestyle choices should be considered throughout drugdevelopment to the point of treatment and continuing patient care.
As such, it has been proposed that inhibiting CDK7 would provide a potent means of inhibiting cell cycle progression, which may be especially relevant given that there is compelling evidence from gene knockout studies in mice for lack of an absolute requirement for CDK2, CDK4 and CDK6 for the cell cycle at least in most cell types (M alumbres et al.,
said study senior author Brad Bernstein , an institute member at Broad and director of the Gene Regulation Observatory at Broad. “We We found that IDH mutations are like a ticking time bomb that allows brain tumor cells to grow slowly and hide from the immune system while they acquire more dangerous mutations. Nature Cancer.
Founded in 2021, SynaptixBio is working to develop therapies for TUBB4A leukodystrophies – a group of rare and severe neurological disorders. Co-founder and CEO Dr Dan Williams brings over 20 years of experience in biochemistry and drugdevelopment, with a strong background in research and clinical trials.
Learnings regarding immune geography and cell:cell contact are increasingly important as we consider how best to advance cell therapies for diverse hematologic malignancies and solid tumors ( www.aletabio.com ). This was an interesting finding and one that I think remains under-appreciated by the immuno-oncology drugdevelopment field.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content